HomeCompareFRLN vs CL

FRLN vs CL: Dividend Comparison 2026

FRLN yields 30.82% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRLN wins by $97.9K in total portfolio value
10 years
FRLN
FRLN
● Live price
30.82%
Share price
$6.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.7K
Annual income
$18,790.33
Full FRLN calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — FRLN vs CL

📍 FRLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRLNCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRLN + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRLN pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRLN
Annual income on $10K today (after 15% tax)
$2,619.41/yr
After 10yr DRIP, annual income (after tax)
$15,971.78/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, FRLN beats the other by $11,380.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRLN + CL for your $10,000?

FRLN: 50%CL: 50%
100% CL50/50100% FRLN
Portfolio after 10yr
$89.8K
Annual income
$12,096.14/yr
Blended yield
13.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

FRLN
Analyst Ratings
2
Buy
5
Hold
Consensus: Hold
Altman Z
-16.9
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRLN buys
0
CL buys
0
No recent congressional trades found for FRLN or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRLNCL
Forward yield30.82%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$138.7K$40.8K
Annual income after 10y$18,790.33$5,401.96
Total dividends collected$95.7K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: FRLN vs CL ($10,000, DRIP)

YearFRLN PortfolioFRLN Income/yrCL PortfolioCL Income/yrGap
1← crossover$13,782$3,081.66$11,012$312.01+$2.8KFRLN
2$18,716$3,969.20$12,196$412.95+$6.5KFRLN
3$25,063$5,037.57$13,599$549.66+$11.5KFRLN
4$33,122$6,304.80$15,288$736.64+$17.8KFRLN
5$43,228$7,787.05$17,353$995.28+$25.9KFRLN
6$55,752$9,498.01$19,926$1,357.80+$35.8KFRLN
7$71,103$11,448.37$23,194$1,873.82+$47.9KFRLN
8$89,726$13,645.43$27,439$2,621.52+$62.3KFRLN
9$112,099$16,092.82$33,088$3,727.38+$79.0KFRLN
10$138,737$18,790.33$40,806$5,401.96+$97.9KFRLN

FRLN vs CL: Complete Analysis 2026

FRLNStock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Full FRLN Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this FRLN vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRLN vs SCHDFRLN vs JEPIFRLN vs OFRLN vs KOFRLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.